Skip to content
2000
image of Targeting STAT3 in Breast Cancer Using Innovative Natural and Synthetic Scaffolds to Trigger Apoptosis, Autophagy, and Halt Tumor Progression

Abstract

Introduction

Signal Transducer and Activator of Transcription 3 (STAT3) is a key mediator in Breast Cancer (BC) progression, contributing to tumor proliferation, metastasis, survival, and resistance to chemotherapy. Phosphorylation of STAT3 at tyrosine 705 promotes its dimerization and nuclear translocation, where it activates oncogenic transcriptional programs. Due to its central role in BC pathogenesis, STAT3 has emerged as a promising molecular target for therapeutic intervention.

Objective

To synthesize, characterize, and evaluate the anticancer efficacy of synthetic and natural compounds with a focus on their ability to inhibit STAT3 phosphorylation, suppress breast cancer cell proliferation, and induce apoptosis and autophagy.

Methods

A comprehensive literature review was conducted using databases such as PubMed, Scopus, Relemed, and ResearchGate. Relevant studies were identified that examined the synthesis, molecular mechanisms, and therapeutic potential of STAT3 inhibitors. Synthetic derivatives and phytochemicals were considered for their inhibitory effects on STAT3 activation and associated cellular outcomes in breast cancers.

Results

Several synthetic and natural compounds demonstrated significant inhibitory effects on STAT3 phosphorylation, leading to reduced breast cancer cell proliferation, migration, and survival. These agents effectively induced apoptosis and, in some cases, autophagy, highlighting their multifaceted anti-tumor mechanisms and elucidating the potential of these compounds as lead candidates for further preclinical and clinical development.

Conclusion

Targeting STAT3 can be a significant therapeutic strategy, as both synthetic and natural compounds capable of inhibiting STAT3 signaling have been shown in preclinical studies. These findings provide valuable insights for cancer biologists, molecular researchers, and clinicians to explore STAT3 inhibitors as potential breast cancer therapeutics.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdt/10.2174/0113894501407510251202050624
2026-01-07
2026-02-26

  • From This Site

    /content/journals/cdt/10.2174/0113894501407510251202050624
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ghoncheh M. Pournamdar Z. Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac. J. Cancer Prev. 2016 17 S3 43 46 10.7314/apjcp.2016.17.s3.43 27165206
    [Google Scholar]
  2. Yu H. Lee H. Herrmann A. Buettner R. Jove R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer 2014 14 11 736 746 10.1038/nrc3818 25342631
    [Google Scholar]
  3. Lee H. Deng J. Kujawski M. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 2010 16 12 1421 1428 10.1038/nm.2250 21102457
    [Google Scholar]
  4. Chang S. Kim Y.H. Kim Y.J. Taurodeoxycholate increases the number of myeloid-derived suppressor cells that ameliorate sepsis in mice. Front. Immunol. 2018 9 1984 10.3389/fimmu.2018.01984 30279688
    [Google Scholar]
  5. Yuan J. Zhang F. Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci. Rep. 2015 5 1 17663 10.1038/srep17663 26631279
    [Google Scholar]
  6. Azad S.M.A.K. Meem J.N. Shaikat A.H. Targeting STAT3-mediated autophagy with small molecules in cancer treatment – A comprehensive review. Clin Tradit Med Pharmacol 2024 5 690 200174 10.1016/j.ctmp.2024.200174
    [Google Scholar]
  7. Bhattacharya S. Ray R.M. Johnson L.R. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J. 2005 392 2 335 344 10.1042/BJ20050465 16048438
    [Google Scholar]
  8. Qin J.J. Yan L. Zhang J. Zhang W.D. STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review. J. Exp. Clin. Cancer Res. 2019 38 1 195 10.1186/s13046‑019‑1206‑z 31088482
    [Google Scholar]
  9. Manore S.G. Doheny D.L. Wong G.L. Lo H.W. IL-6/JAK/STAT3 signaling in breast cancer metastasis: Biology and treatment. Front. Oncol. 2022 12 866014 10.3389/fonc.2022.866014 35371975
    [Google Scholar]
  10. Hawcroft G. Loadman P.M. Belluzzi A. Hull M.A. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells. Neoplasia 2010 12 8 618 IN2 10.1593/neo.10388 20689756
    [Google Scholar]
  11. Symmans F.W. Breast cancer response to paclitaxel in vivo. Drug Resist. Updat. 2001 4 5 297 302 10.1054/drup.2001.0218 11991683
    [Google Scholar]
  12. Garg M. Shanmugam M.K. Bhardwaj V. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Med. Res. Rev. 2021 41 3 1291 1336 10.1002/med.21761 33289118
    [Google Scholar]
  13. Xie X. Liu Y. Liu J. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 2021 27 4 620 621 10.1038/s41591‑021‑01270‑4 33558724
    [Google Scholar]
  14. Wen F. Xu L. Ouyang G. Kou G. Retail investor attention and stock price crash risk: Evidence from China. Int. Rev. Financ. Anal. 2019 65 101376 10.1016/j.irfa.2019.101376
    [Google Scholar]
  15. Tegowski M. Fan C. Baldwin A.S. Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2. J. Biol. Chem. 2018 293 41 15977 15990 10.1074/jbc.RA118.003719 30131338
    [Google Scholar]
  16. Shakya R. Byun M.R. Joo S.H. Chun K.S. Choi J.S. Domperidone exerts antitumor activity in triple-negative breast cancer cells by modulating reactive oxygen species and JAK/STAT3 signaling. Biomol. Ther. 2023 31 6 692 699 10.4062/biomolther.2023.173 37899746
    [Google Scholar]
  17. Kim Y.J. Kim J.Y. Lee N. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. Biochem. Biophys. Res. Commun. 2017 486 4 1069 1076 10.1016/j.bbrc.2017.03.164 28373070
    [Google Scholar]
  18. Singh P. Sahoo S.K. Piperlongumine loaded PLGA nanoparticles inhibit cancer stem-like cells through modulation of STAT3 in mammosphere model of triple negative breast cancer. Int. J. Pharm. 2022 616 121526 10.1016/j.ijpharm.2022.121526 35104598
    [Google Scholar]
  19. Lee J.H. Mohan C.D. Deivasigamani A. Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma. J. Adv. Res. 2020 26 83 94 10.1016/j.jare.2020.07.004 33133685
    [Google Scholar]
  20. Cheng Y. Holloway M.P. Nguyen K. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol. Cancer Ther. 2014 13 3 675 686 10.1158/1535‑7163.MCT‑13‑0416 24431073
    [Google Scholar]
  21. Byun W.S. Bae E.S. Cui J. Park H.J. Oh D.C. Lee S.K. Antitumor activity of pulvomycin via targeting activated-STAT3 signaling in docetaxel-resistant triple-negative breast cancer cells. Biomedicines 2021 9 4 436 10.3390/biomedicines9040436 33920736
    [Google Scholar]
  22. Jung Y.Y. Ha I.J. Um J.Y. Sethi G. Ahn K.S. Fangchinoline diminishes STAT3 activation by stimulating oxidative stress and targeting SHP-1 protein in multiple myeloma model. J. Adv. Res. 2022 35 245 257 10.1016/j.jare.2021.03.008 35024200
    [Google Scholar]
  23. Jampilek J. Heterocycles in medicinal chemistry. Molecules 2019 24 21 3839 10.3390/molecules24213839
    [Google Scholar]
  24. Taylor A.P. Robinson R.P. Fobian Y.M. Blakemore D.C. Jones L.H. Fadeyi O. Modern advances in heterocyclic chemistry in drug discovery. Org. Biomol. Chem. 2016 14 28 6611 6637 10.1039/C6OB00936K 27282396
    [Google Scholar]
  25. Filipe H.A.L. Loura L.M.S. Molecular dynamics simulations: Advances and applications. Molecules 2022 27 7 2105 10.3390/molecules27072105 35408504
    [Google Scholar]
  26. Khatun S. Singh A. Bader G.N. Sofi F.A. Imidazopyridine, a promising scaffold with potential medicinal applications and structural activity relationship (SAR): Recent advances. J. Biomol. Struct. Dyn. 2022 40 24 14279 14302 10.1080/07391102.2021.1997818 34779710
    [Google Scholar]
  27. Su J.C. Chang C.H. Wu S.H. Shiau C.W. Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1. J. Enzyme Inhib. Med. Chem. 2018 33 1 1248 1255 10.1080/14756366.2018.1497019 30261753
    [Google Scholar]
  28. Godse P. Kumar P. Yewalkar N. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways. Anticancer. Agents Med. Chem. 2013 13 9 1460 1466 10.2174/18715206113136660341 24102269
    [Google Scholar]
  29. Ghosh S. Durgvanshi S. Agarwal S. Raghunath M. Sinha J.K. Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer’s disease. Curr. Neuropharmacol. 2020 18 9 883 903 10.2174/1570159X18666200429011823 32348223
    [Google Scholar]
  30. Wang S. Zhou D. Xu Z. Anti-tumor drug targets analysis: Current insight and future prospect. Curr. Drug Targets 2019 20 11 1180 1202 10.2174/1389450120666190402145325 30947670
    [Google Scholar]
  31. Zheng Q. Dong H. Mo J. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics 2021 11 2 824 840 10.7150/thno.49600 33391507
    [Google Scholar]
  32. Liu D. Hu G. Long G. Qiu H. Mei Q. Hu G. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol. Sin. 2012 33 5 682 690 10.1038/aps.2012.18 22504904
    [Google Scholar]
  33. LaPorte M.G. Wang Z. Colombo R. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. Bioorg. Med. Chem. Lett. 2016 26 15 3581 3585 10.1016/j.bmcl.2016.06.017 27381083
    [Google Scholar]
  34. You D. Hug L. Ejdemyr S. United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: A systematic analysis by the UN inter-agency group for child mortality estimation. Lancet 2015 386 10010 2275 2286 10.1016/S0140‑6736(15)00120‑8 26361942
    [Google Scholar]
  35. Wang Y. Boulic M. Phipps R. Plagmann M. Cunningham C. Guyot G. Field performance of a solar air heater used for space heating and ventilation – A case study in New Zealand primary schools. J. Build. Eng. 2023 106802 10.1016/j.jobe.2023.106802
    [Google Scholar]
  36. Zhan G. Wei T. Xie H. Autophagy inhibition mediated by trillin promotes apoptosis in hepatocellular carcinoma cells via activation of mTOR/STAT3 signaling. Naunyn Schmiedebergs Arch. Pharmacol. 2024 397 3 1575 1587 10.1007/s00210‑023‑02700‑5 37676495
    [Google Scholar]
  37. Remy J. Linder B. Weirauch U. STAT3 enhances sensitivity of glioblastoma to drug-induced autophagy-dependent cell death. Cancers 2022 14 2 339 10.3390/cancers14020339 35053502
    [Google Scholar]
  38. Liu S. Wang X. Liu M. Zhu J. Towards better analysis of machine learning models: A visual analytics perspective. Visual Informatics 2017 1 1 48 56 10.1016/j.visinf.2017.01.006
    [Google Scholar]
  39. Mok T.S.K. Wu Y.L. Kudaba I. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 2019 393 10183 1819 1830 10.1016/S0140‑6736(18)32409‑7 30955977
    [Google Scholar]
  40. Zu Z.Y. Jiang M.D. Xu P.P. Coronavirus disease 2019 (COVID-19): A perspective from China. Radiology 2020 296 2 E15 E25 10.1148/radiol.2020200490 32083985
    [Google Scholar]
  41. Huang C. Wang Y. Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 395 10223 497 506 10.1016/S0140‑6736(20)30183‑5 31986264
    [Google Scholar]
  42. Sun M. Gadad S.S. Kim D.S. Kraus W.L. Discovery, annotation, and functional analysis of long noncoding RNAs controlling cell-cycle gene expression and proliferation in breast cancer cells. Mol. Cell 2015 59 4 698 711 10.1016/j.molcel.2015.06.023 26236012
    [Google Scholar]
  43. Wang B. Lv X.L. Feng D. Highly stable Zr (IV)-based metal–organic frameworks for the detection and removal of antibiotics and organic explosives in water. J. Am. Chem. Soc. 2016 138 19 6204 6216 10.1021/jacs.6b01663 27090616
    [Google Scholar]
  44. Guo Y.R. Cao Q.D. Hong Z.S. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – An update on the status. Mil. Med. Res. 2020 7 1 11 10.1186/s40779‑020‑00240‑0
    [Google Scholar]
  45. Zheng S. Jayasumana S. Romera-Paredes B. Conditional random fields as recurrent neural networks. IEEE International Conference on Computer Vision (ICCV) Santiago, Chile 2015 1529 1537 10.1109/ICCV.2015.179
    [Google Scholar]
  46. Byun W.S. Lim H. Hong J. Design, synthesis, and biological activity of marinacarboline analogues as STAT3 pathway inhibitors for docetaxel-resistant triple-negative breast cancer. J. Med. Chem. 2023 66 4 3106 3133 10.1021/acs.jmedchem.2c01115 36786551
    [Google Scholar]
  47. Liu X Gao Y Yang F A Review of Cryptotanshinone and its Nanoformulation in Cancer Therapy. Anticancer Agents Med Chem 2025 25 16 1188 1197 10.2174/0118715206372305250319064431 40176695 2025
    [Google Scholar]
  48. Deng X.S. Wang S. Deng A. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012 11 2 367 376 10.4161/cc.11.2.18813 22189713
    [Google Scholar]
  49. Gariboldi M.B. Ravizza R. Molteni R. Osella D. Gabano E. Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007 258 2 181 188 10.1016/j.canlet.2007.08.019 17920763
    [Google Scholar]
  50. Oh E. Kim Y.J. An H. Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition. Int. J. Cancer 2018 143 8 1978 1993 10.1002/ijc.31585 29744876
    [Google Scholar]
  51. Reddy D. Sekar C. Gaur C. Causon D.B.J. Pillai M. Identification Confirmation of Structurally Related Degradation Products of Simvastatin. 2018 Available from: https://sciex.com/content/dam/SCIEX/pdf/tech-notes/all/Identification-Confirmation-of-Structurally-Related-Degradation-Products-of-Simvastatin.pdf
    [Google Scholar]
  52. Dees S. Pontiggia L. Jasmin J.F. Mercier I. Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer. Cancer Biol. Ther. 2020 21 6 506 521 10.1080/15384047.2020.1726718 32164483
    [Google Scholar]
  53. Park S.K. Byun W.S. Lee S. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction. Biochem. Pharmacol. 2020 178 114053 10.1016/j.bcp.2020.114053 32450253
    [Google Scholar]
  54. Pan L. Chen X. Rassool F.V. Li C. Lin J. LLL12B, a novel small-molecule STAT3 inhibitor, induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells. Biomedicines 2022 10 8 2003 10.3390/biomedicines10082003 36009550
    [Google Scholar]
  55. Pan L. Chen X. Fu S. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer. Breast Cancer Res. Treat. 2020 181 1 31 41 10.1007/s10549‑020‑05613‑6 32240456
    [Google Scholar]
  56. Zhong Y. Deng L. Shi S. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacol. Sin. 2022 43 4 1013 1023 10.1038/s41401‑021‑00718‑0 34267347
    [Google Scholar]
  57. Yang B. Shen J.W. Zhou D.H. Precise discovery of a STAT3 inhibitor from Eupatorium lindleyanum and evaluation of its activity of anti-triple-negative breast cancer. Nat. Prod. Res. 2019 33 4 477 485 10.1080/14786419.2017.1396596 29086600
    [Google Scholar]
  58. Cho T.M. Kim J.Y. Kim Y.J. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Cancer Lett. 2019 447 141 153 10.1016/j.canlet.2019.01.029 30703411
    [Google Scholar]
  59. Chun J. Li R.J. Cheng M.S. Kim Y.S. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett. 2015 357 1 393 403 10.1016/j.canlet.2014.11.049 25434800
    [Google Scholar]
  60. Lee H.J. Seo N.J. Jeong S.J. Oral administration of penta-O-galloyl- -D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition. Carcinogenesis 2011 32 6 804 811 10.1093/carcin/bgr015 21289371
    [Google Scholar]
  61. Dai X. Yin C. Zhang Y. Osthole inhibits triple negative breast cancer cells by suppressing STAT3. J. Exp. Clin. Cancer Res. 2018 37 1 322 10.1186/s13046‑018‑0992‑z 30577812
    [Google Scholar]
  62. Cantharidin induces apoptosis and suppresses cell migration and invasion of MDA-MB-231 human breast cancer cells through inhibition of EGFR-STAT3 signaling. 2017 Available from: https://hdl.handle.net/10371/137927
  63. Alsamri H. El Hasasna H. Al Dhaheri Y. Eid A.H. Attoub S. Iratni R. Carnosol, a natural polyphenol, inhibits migration, metastasis, and tumor growth of breast cancer via a ROS-dependent proteasome degradation of STAT3. Front. Oncol. 2019 9 743 10.3389/fonc.2019.00743 31456939
    [Google Scholar]
  64. Shakya R. Park G.H. Joo S.H. Shim J.H. Choi J.S. Hydroxyzine induces cell death in triple-negative breast cancer cells via mitochondrial superoxide and modulation of Jak2/STAT3 signaling. Biomol. Ther. 2022 30 6 585 592 10.4062/biomolther.2022.121 36305293
    [Google Scholar]
  65. Qu Z. Lin Y. Mok D.K.W. Bian Q. Tai W.C.S. Chen S. Brevilin A, a natural sesquiterpene lactone inhibited the growth of triple-negative breast cancer cells via Akt/mTOR and STAT3 signaling pathways. OncoTargets Ther. 2020 13 5363 5373 10.2147/OTT.S256833 32606754
    [Google Scholar]
  66. Huang Q. Li S. Zhang L. CAPE-p NO2 inhibited the growth and metastasis of triple-negative breast cancer via the EGFR/STAT3/Akt/E-cadherin signaling pathway. Front. Oncol. 2019 9 461 10.3389/fonc.2019.00461 31214503
    [Google Scholar]
  67. Mallory H. Reddy D. Xiong L. Zhang J. Pohl K. Comparative analysis of intact AAV8 capsid proteins derived from SF9 and HEK293 cell lines. 2021 Available from: https://sciex.com/diagnostics
  68. Mallory H. Selen E. Reddy D. Xiong L. Pohl K. A powerful processing workflow for the analysis of intact AAV8 capsid proteins with challenging chromatography. 2022 Available from: https://sciex.com/content/dam/SCIEX/tech-notes/biopharma/ruo-mkt-02-14583-a/RUO-MKT-02-14583-A_Luye%20AAV%20intact%20analysis%20with%20X500B%20and%20BE.pdf
  69. Lee M.M.L. Chan B.D. Wong W.Y. Anti-cancer activity of Centipeda minima extract in triple negative breast cancer via inhibition of AKT, NF-κB, and STAT3 signaling pathways. Front. Oncol. 2020 10 491 10.3389/fonc.2020.00491 32328465
    [Google Scholar]
  70. Xie Q. Yang Z. Huang X. Ilamycin C induces apoptosis and inhibits migration and invasion in triple-negative breast cancer by suppressing IL-6/STAT3 pathway. J. Hematol. Oncol. 2019 12 1 60 10.1186/s13045‑019‑0744‑3 31186039
    [Google Scholar]
  71. Wang X. Shi W. Wang X. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer. Cell Death Discov. 2023 9 1 355 10.1038/s41420‑023‑01658‑w 37752122
    [Google Scholar]
  72. Song H. Luo Q. Deng X. VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer. Exp. Mol. Med. 2019 51 11 1 13 10.1038/s12276‑019‑0338‑8 31748508
    [Google Scholar]
  73. El Hasasna H. Saleh A. Samri H.A. Rhus coriaria suppresses angiogenesis, metastasis and tumor growth of breast cancer through inhibition of STAT3, NFκB and nitric oxide pathways. Sci. Rep. 2016 6 1 21144 10.1038/srep21144 26888313
    [Google Scholar]
  74. Ko H. Lee J. Kim H. Novel galiellalactone analogues can target STAT3 phosphorylation and cause apoptosis in triple-negative breast cancer. Biomolecules 2019 9 5 170 10.3390/biom9050170 31058868
    [Google Scholar]
  75. Yamashita N. Kondo M. Zhao S. Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway. Bioorg. Med. Chem. Lett. 2017 27 11 2608 2612 10.1016/j.bmcl.2017.03.061 28427809
    [Google Scholar]
  76. Zhang W. Guo J. Li S. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy. Sci. Rep. 2017 7 1 46352 10.1038/srep46352 28397855
    [Google Scholar]
  77. You Y. Chen X. Chen X. Jiawei yanghe decoction suppresses breast cancer by regulating immune responses via JAK2/STAT3 signaling pathway. J. Ethnopharmacol. 2023 316 116358 10.1016/j.jep.2023.116358 36933872
    [Google Scholar]
  78. Zhang Z.L. Jiang Q.C. Wang S.R. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Cancer 2018 25 2 233 242 10.1007/s12282‑017‑0821‑9 29181822
    [Google Scholar]
  79. Yan W. Tu B. Liu Y. Suppressive effects of plumbagin on invasion and migration of breast cancer cells via the inhibition of STAT3 signaling and down-regulation of inflammatory cytokine expressions. Bone Res. 2013 1 4 362 370 10.4248/BR201304007 26273514
    [Google Scholar]
  80. Aryappalli P. Al-Qubaisi S.S. Attoub S. The IL-6/STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells. Front. Oncol. 2017 7 167 10.3389/fonc.2017.00167 28856117
    [Google Scholar]
  81. Brotherton-Pleiss C. Yue P. Zhu Y. Discovery of novel azetidine amides as potent small-molecule STAT3 inhibitors. J. Med. Chem. 2021 64 1 695 710 10.1021/acs.jmedchem.0c01705 33352047
    [Google Scholar]
  82. Wang L. Shi H. Zhang X. I157172, a novel inhibitor of cystathionine γ-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3. Oncol. Rep. 2019 41 1 427 436 10.3892/or.2018.6798 30365149
    [Google Scholar]
  83. To N.B. Nguyen Y.T.K. Moon J.Y. Ediriweera M.K. Cho S.K. Pentadecanoic acid, an odd-chain fatty acid, suppresses the stemness of MCF-7/SC human breast cancer stem-like cells through JAK2/STAT3 signaling. Nutrients 2020 12 6 1663 10.3390/nu12061663 32503225
    [Google Scholar]
  84. Mantaj J. Rahman S.M.A. Bokshi B. Crispene E, a cis-clerodane diterpene inhibits STAT3 dimerization in breast cancer cells. Org. Biomol. Chem. 2015 13 13 3882 3886 10.1039/C5OB00052A 25721973
    [Google Scholar]
  85. Dong Y. Yin S. Li J. Jiang C. Ye M. Hu H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis 2011 16 4 394 403 10.1007/s10495‑011‑0573‑5 21259053
    [Google Scholar]
  86. So J.Y. Smolarek A.K. Salerno D.M. Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One 2013 8 1 e54020 10.1371/journal.pone.0054020 23326564
    [Google Scholar]
  87. Kim N.H. Park H.J. Oh M.K. Kim I.S. Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells. BMB Rep. 2013 46 1 59 64 10.5483/BMBRep.2013.46.1.123 23351386
    [Google Scholar]
  88. Al-Jomah N. Al-Mohanna F.H. Aboussekhra A. Tocilizumab suppresses the pro-carcinogenic effects of breast cancer-associated fibroblasts through inhibition of the STAT3/AUF1 pathway. Carcinogenesis 2021 42 12 1439 1448 10.1093/carcin/bgab102 34718441
    [Google Scholar]
  89. Chen J. Li N. Liu B. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways. Life Sci. 2020 248 117469 10.1016/j.lfs.2020.117469 32109485
    [Google Scholar]
  90. Chen W. Wang H. Cheng M. Isoharringtonine inhibits breast cancer stem-like properties and STAT3 signaling. Biomed. Pharmacother. 2018 103 435 442 10.1016/j.biopha.2018.04.076 29679903
    [Google Scholar]
  91. Lv C. Huang Y. Huang R. Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells. Mol. Ther. Oncolytics 2022 24 340 354 10.1016/j.omto.2021.12.025 35118192
    [Google Scholar]
  92. Zhang J. Li Y. Wang J.G. Feng J.Y. Huang G.D. Luo C.G. Dihydroartemisinin affects STAT3/DDA1 signaling pathway and reverses breast cancer resistance to cisplatin. Am. J. Chin. Med. 2023 51 2 445 459 10.1142/S0192415X23500234 36891981
    [Google Scholar]
  93. Kim S. Kil W.H. Lee J. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. Oncol. Rep. 2014 32 6 2666 2672 10.3892/or.2014.3514 25269647
    [Google Scholar]
  94. Schust J. Sperl B. Hollis A. Mayer T.U. Berg T. Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006 13 11 1235 1242 10.1016/j.chembiol.2006.09.018 17114005
    [Google Scholar]
  95. Wei M. Xie M. Zhang Z. Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer. Eur. J. Med. Chem. 2020 206 112677 10.1016/j.ejmech.2020.112677 32823005
    [Google Scholar]
  96. Choi H.S. Kim J.H. Kim S.L. Catechol derived from aronia juice through lactic acid bacteria fermentation inhibits breast cancer stem cell formation via modulation Stat3/IL‐6 signaling pathway. Mol. Carcinog. 2018 57 11 1467 1479 10.1002/mc.22870 29964299
    [Google Scholar]
  97. Hosea R. Hardiany N. Ohneda O. Wanandi S. Glucosamine decreases the stemness of human ALDH+ breast cancer stem cells by inactivating STAT3. Oncol. Lett. 2018 16 4 4737 4744 10.3892/ol.2018.9222 30214607
    [Google Scholar]
  98. Li Y. Gan C. Zhang Y. Inhibition of Stat3 signaling pathway by natural product pectolinarigenin attenuates breast cancer metastasis. Front. Pharmacol. 2019 10 1195 10.3389/fphar.2019.01195 31649548
    [Google Scholar]
  99. Wang J. Xu J. Xing G. Lycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathway. Acta Biochim. Biophys. Sin. 2017 49 9 771 779 10.1093/abbs/gmx076 28910973
    [Google Scholar]
  100. Susmitha G.D. Miyazato K. Ogura K. Yokoyama S. Hayakawa Y. Anti-metastatic effects of baicalein by targeting STAT3 activity in breast cancer cells. Biol. Pharm. Bull. 2020 43 12 1899 1905 10.1248/bpb.b20‑00571 33268707
    [Google Scholar]
  101. Wang J. Zhang L. Chen G. Small molecule 1′-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway. Breast Cancer Res. Treat. 2014 148 2 279 289 10.1007/s10549‑014‑3165‑6 25301089
    [Google Scholar]
  102. Shi X. Lai Y. Liu W. Zhang X. Cang Y. Natural compound Byakangelicin suppresses breast tumor growth and motility by regulating SHP-1/JAK2/STAT3 signal pathway. Biochem. Biophys. Res. Commun. 2024 706 149758 10.1016/j.bbrc.2024.149758 38484571
    [Google Scholar]
  103. Leong H. Mathur P.S. Greene G.L. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res. Treat. 2009 117 3 505 515 10.1007/s10549‑008‑0196‑x 18821062
    [Google Scholar]
  104. Sp N. Kang D. Joung Y. Nobiletin inhibits angiogenesis by regulating Src/FAK/STAT3-mediated signaling through PXN in ER+ breast cancer cells. Int. J. Mol. Sci. 2017 18 5 935 10.3390/ijms18050935 28468300
    [Google Scholar]
  105. Kwon Y.S. Chun S.Y. Kim M.K. Nan H.Y. Lee C. Kim S. Mistletoe extract targets the STAT3-FOXM1 pathway to induce apoptosis and inhibits metastasis in breast cancer cells. Am. J. Chin. Med. 2021 49 2 487 504 10.1142/S0192415X21500221 33622211
    [Google Scholar]
  106. Park Y.R. Jee W. Park S.M. Viscum album induces apoptosis by regulating STAT3 signaling pathway in breast cancer cells. Int. J. Mol. Sci. 2023 24 15 11988 10.3390/ijms241511988 37569363
    [Google Scholar]
  107. Kohandel Z. Farkhondeh T. Aschner M. Pourbagher-Shahri A.M. Samarghandian S. STAT3 pathway as a molecular target for resveratrol in breast cancer treatment. Cancer Cell Int. 2021 21 1 468 10.1186/s12935‑021‑02179‑1 34488773
    [Google Scholar]
  108. Kim S.R. Seo H.S. Choi H-S. Trichosanthes kirilowii ethanol extract and cucurbitacin D inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. Evid. Based Complement. Alternat. Med. 2013 2013 1 975350 10.1155/2013/975350 24194785
    [Google Scholar]
  109. Ahmad A. Sarkar S.H. Aboukameel A. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis 2012 33 12 2450 2456 10.1093/carcin/bgs290 22971573
    [Google Scholar]
  110. Seo H-S. Ku J.M. Choi H-S. Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDA-MB-453 breast cancer cells. Anticancer Res. 2014 34 6 2869 2882 24922650
    [Google Scholar]
  111. Khan M.W. Saadalla A. Ewida A.H. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol. Immunother. 2018 67 1 13 23 10.1007/s00262‑017‑2057‑0 28875329
    [Google Scholar]
  112. Lin L. Hutzen B. Zuo M. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010 70 6 2445 2454 10.1158/0008‑5472.CAN‑09‑2468 20215512
    [Google Scholar]
  113. Yue P. Lopez-Tapia F. Paladino D. Hydroxamic acid and benzoic acid–based stat3 inhibitors suppress human glioma and breast cancer phenotypes in vitro and in vivo. Cancer Res. 2016 76 3 652 663 10.1158/0008‑5472.CAN‑14‑3558 26088127
    [Google Scholar]
  114. Thakur R. Trivedi R. Rastogi N. Singh M. Mishra D.P. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci. Rep. 2015 5 1 10194 10.1038/srep10194 25973915
    [Google Scholar]
  115. Gyamfi J. Lee Y.H. Min B.S. Choi J. Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis. Sci. Rep. 2019 9 1 11336 10.1038/s41598‑019‑47707‑2 31383893
    [Google Scholar]
  116. Su Y. Yang J. Wang M.M. Cyclometalated iridium(III) complexes as anti-breast cancer and anti-metastasis agents via STAT3 inhibition. J. Inorg. Biochem. 2024 251 112427 10.1016/j.jinorgbio.2023.112427 37979498
    [Google Scholar]
  117. Zhang X. Sun Y. Pireddu R. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013 73 6 1922 1933 10.1158/0008‑5472.CAN‑12‑3175 23322008
    [Google Scholar]
  118. Siddiquee K.A.Z. Gunning P.T. Glenn M. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2007 2 12 787 798 10.1021/cb7001973 18154266
    [Google Scholar]
  119. Alaaeldin R. Ali F.E.M. Bekhit A.A. Zhao Q.L. Fathy M. Inhibition of NF-kB/IL-6/JAK2/STAT3 pathway and epithelial-mesenchymal transition in breast cancer cells by azilsartan. Molecules 2022 27 22 7825 10.3390/molecules27227825 36431925
    [Google Scholar]
  120. Wang X. Zhang Y. Zhang X. Tian W. Feng W. Chen T. The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition. Int. J. Oncol. 2012 40 4 1189 1195 10.3892/ijo.2011.1298 22179587
    [Google Scholar]
  121. Nalla L.V. Dharavath A. Behera S.K. Khairnar A. Alpha mangostin inhibits proliferation, migration, and invasion of human breast cancer cells via STAT3 inhibition. Adv. Cancer Biol. Metastasis 2023 7 9 100089 10.1016/j.adcanc.2023.100089
    [Google Scholar]
  122. Liu Z. Ge X. Gu Y. Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo. Biomed. Pharmacother. 2020 121 109502 10.1016/j.biopha.2019.109502 31707351
    [Google Scholar]
  123. Burke W.M. Jin X. Lin H.J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001 20 55 7925 7934 10.1038/sj.onc.1204990 11753675
    [Google Scholar]
/content/journals/cdt/10.2174/0113894501407510251202050624
Loading
Targeting STAT3 in Breast Cancer Using Innovative Natural and Synthetic Scaffolds to Trigger Apoptosis, Autophagy, and Halt Tumor Progression
Bentham Science Publishers ; https://doi.org/10.2174/0113894501407510251202050624
/content/journals/cdt/10.2174/0113894501407510251202050624
/content/journals/cdt/10.2174/0113894501407510251202050624
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: synthetic compounds ; apoptosis ; natural products ; molecular oncology ; STAT3 ; targeted therapy ; breast cancer ; phosphorylation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test